GuruFocus·Jun 25, 2026
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Nuvalent, Inc.(NUVL)Earnings, Financials & Key Ratios
NUVL•NASDAQ
$123.77
Price updated Jul 7, 2026
AboutNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA$0
- Net Income-$425M-63.1%
- EPS (Diluted)-5.85-48.9%
- ROE-36.7%-24.6%
NUVL Price & Volume
Nuvalent, Inc. (NUVL) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical R&D Drives Capital Consumption
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution risk
Key Thesis Takeaways
- Nuvalent is currently navigating a critical transition into late-stage clinical development, characterized by a sharp escalation in R&D spending to support its lead assets, NVL-520 and NVL-655.
- While the company maintains a robust equity base of $1.2 billion, its reliance on external financing to offset persistent operating losses suggests a binary risk profile tied to future clinical trial outcomes.
- Investors should monitor the rapid depletion of cash reserves, which fell from $261.7 million in 2025Q4 to $159.7 million in 2026Q1, as the firm approaches potential commercialization milestones.
Verdict Logic
while the company holds $159.7 million in cash, the rapid quarterly burn rate of $92.4 million necessitates careful monitoring of future financing needs and clinical trial execution.
NUVL Growth Metrics
Nuvalent, Inc. (NUVL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-49.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.04%
Return on Capital
10 Years-132.04%
5 Years-29.18%
3 Years-30.48%
Last Year-34.39%
NUVL Recent Earnings
Nuvalent, Inc. (NUVL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.39-3.0%
$1.35
Rev
—
$486,000
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.29+12.8%
$1.48
Rev
—
$7M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.70-22.3%
$1.39
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.31-3.1%
$1.27
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.39vs $1.35-3.0% | —vs $486,000 |
| Q1 2026 | Feb 26, 2026 | $1.29vs $1.48+12.8% | —vs $7M |
| Q4 2025 | Oct 30, 2025 | $1.70vs $1.39-22.3% | — |
| Q3 2025 | Aug 7, 2025 | $1.31vs $1.27-3.1% | — |
Based on last 12 quarters of dataView full earnings history →
Latest NUVL News
Recent stock market news and headlines for Nuvalent, Inc. (NUVL)
247 Wallst·Jun 24, 2026
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and MorePre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old saying, "when the chips are down", that was the poster child phrase for Tuesday's session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When... Here Are Wednesday's Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
GlobeNewsWire·Jun 16, 2026
NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSKMONSEY, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Nuvalent, Inc. (Nasdaq: NUVL) (“NUVL”) for $124.00 per share in cash to GSK in a tender offer.
Peers Comparison
Key metrics vs top competitors for Nuvalent, Inc. (NUVL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $123.77 | $9.1B | -21.16 | — | — | -36.7% | — | |
| $11.65 | $372.78M | 5.07 | 6774.96% | -256.6% | -17.04% | — | |
| $0.99 | $4.4M | -0.16 | — | — | -729.89% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $18.36 | $5.71B | -41.73 | — | — | -77.01% | — | |
| $60.89 | $2.62B | -38.30 | 146.71% | -9.02% | -14.19% | — |
Compare NUVL vs Peers
Nuvalent, Inc. (NUVL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUVL SEC Filings & Documents
Nuvalent, Inc. (NUVL) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when NUVL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUVL Frequently Asked Questions
Nuvalent, Inc. (NUVL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NUVL profitable?
Nuvalent, Inc. (NUVL) reported a net loss of $450.1M for fiscal year 2025.
Dividend & Returns
What is NUVL's return on equity?
Nuvalent, Inc. (NUVL) has a return on equity (ROE) of -36.7%. Negative ROE indicates the company is unprofitable.
What is Nuvalent, Inc.'s free cash flow?
Nuvalent, Inc. (NUVL) had negative free cash flow of $312.8M in fiscal year 2025, likely due to heavy capital investments.